94 results about "Prostacyclin" patented technology

The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.

The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.

The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C₂-C₁₈ alkyl, branched C₃-C₁₈ alkyl, linear C₂-C₁₈ alkenyl, branched C₃-C₁₈ alkenyl, aryl, aryl-C₁-C₁₈ alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described, for example, for administration via subcutaneous or intravenous infusion to a patient in need of pulmonary hypertension treatment. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom.

The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.

The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.

The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

Cardiovascular disease, including preeclampsia in pregnant women and hypertension in both women and men, are prevented or treated by administering thereto prostacyclin or a prostacyclin analog in combination with one or both of an estrogen and a progestin, which combination is also useful for HRT in peri- and post-menopausal women.

The invention belongs to the field of biomedical materials and relates to a surface functional titanium material. In the surface functional titanium material, the surface of the titanium material has a TiO2 nanometer tube array with the diameter of 30-60nm, and the surface of the TiO2 nanometer tube array is also fixed with a vascular endothelial growth factor (VEGF). A preparation method of the surface functional titanium material comprises the following steps of preparing the TiO2 nanometer tube array with the diameter of 30-60nm on the surface of the titanium material by adopting an anode oxidation process; carrying out silylanization treatment on the surface of the TiO2 nanometer tube array; introducing carboxyl onto the surface of the TiO2 nanometer tube array through chemical reaction; activating the carboxyl by utilizing carbodiimide and succinimide; and fixing the VEGF on the surface of the TiO2 nanometer tube array with the activated carboxyl through contact reaction to obtain the surface functional titanium material. The invention synergistically utilizes the VEGF and a TiO2 nanometer tube array structure with the diameter of 30-60nm to enhance the activity of endothelial cells of the surface of the titanium material and expression of a function index such as prostacyclin and can realize rapid endothelialization of the surface of a titanium substrate intravascular stent.

The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

The invention provides formulations and methods of use of furopyridine-based compositions alone and in combination with one or more various second therapeutic agents for the treatment of human disease. The furopyridine composition may include one or more furopyridine species, of which cicletanine is an example. The furopyridines may take various enantiomeric forms, ranging from pure (−) through (−)-dominant, racemic and (+)-dominant to pure (+). Second agents may be any drug useful in combination with a furopyridine in the treatment of diseases such as, cardiovascular disease (hypertension, restenosis, etc.), diabetes, diabetes complications, and polycystic ovarian syndrome. Some of these diseases are associated with endothelial dysfunction and imbalances of prostacyclin or of reactive oxygen species (ROS) or reactive nitrogen species (RNS).

Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.

The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.

The present invention provides processes for preparing a prostacyclin analogue of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is a linear or branched C_1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.

A method of preventing, arresting, reversing and treatment of atherosclerosis by enhancing the activities of Δ⁶ and Δ⁵ desaturases such that the cell, tissue, and plasma levels of various polyunsaturated fatty acids (PUFAs) and, in particular that of endothelial cells lining the blood vessels will increase. More particularly, the invention is directed to enhance the activities of Δ⁶ and Δ⁵ desaturases that, in turn, will lead to increased production of products of polyunsaturated fatty acids such as prostacyclin (PGI₂), PGI₃, lipoxins, resolvins, protecting, PGE₁ (prostaglandin E₁), nitric oxide, and nitrolipids such that atherosclerotic process will be prevented, arrested, reversed and this will lead to efficient arrest, regression, prevention and/or treatment of even established atherosclerosis and its associated conditions. More particularly, the invention is directed to the delivery of proteins, peptides, lipids, lipoproteins, glycolipids, synthetic chemicals such as statins and their derivatives, troglitazones and their derivatives, and other compounds (synthetic or natural) that have the ability to enhance the activities of Δ⁶ and Δ⁵ desaturases in vivo, also provides methods of efficiently delivering cDNA clones of Δ⁶ and Δ⁵ desaturases and genes of Δ⁶ and Δ⁵ desaturases to endothelial cells and other target cells to prevent, arrest, reverse and treat atherosclerosis.

The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.